Robert Whitfield MD discusses how obesity drugs like BLB1 and Agonist change behavior in ways that could reshape health outcomes over the next decade. The speakers see widespread adoption revealing both benefits and harms as these drugs tackle a lifelong epidemic rooted in entrenched habits.
This is just like, I sat back one day and I was like, oh, my God. A drug that changes behavior but in the correct way, as far as I'm concerned, has never been brought to market with this kind of clear side effect.
I mean, this obesity is like the world epidemic, right? Almost everyone, you know, someone has it. It's not like it's a rare disease or something that is temporary. Right. This is something that builds over a lifetime. And your behavioral choices, you get stuck. You don't want to change it. So what had, you know, bad habits continue to build. So now we have such a large population size of people using it who have similar tendencies and habits. Now you're going to start seeing both the positives and negatives. Yeah.
Just amazing to sit back as a. You know, you look at it like, wow, that's gonna have a lot. I mean, it's probably in 10 years, if we have a little show and say, what had the most impact? BLB1 and Agonist. They. They changed everything. Because ultimately, when you change behavior, the outcome.
